3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Dermatologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
5
Mycosis Fungoides
4
Lymphoma, T-Cell, Cutaneous
4
Sezary Syndrome
2
Lymphoma
2
Leukemia, Myeloid, Acute
2
Carcinoma
2
Thyroid Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Lymphoma, Primary Cutaneous Anaplastic Large Cell
1
Lung Neoplasms
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myelomonocytic, Acute
1
Leukemia, Monocytic, Acute
1
Leukemia, Megakaryoblastic, Acute
1
Leukemia, Erythroblastic, Acute
1
Leukemia
1
Congenital Abnormalities
1
Carcinoma, Intraductal, Noninfiltrating
1
Breast Carcinoma In Situ
1
Anemia, Refractory, with Excess of Blasts
1
Aggression
1
Interventions
Methotrexate
1
Brentuximab Vedotin
1
Bexarotene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Lymphoma, Primary Cutaneous Anaplastic Large Cell
×
Bexarotene
×
Clear all
NCT01578499
2021-01-05
ALCANZA
Takeda
Phase 3
Completed
131 enrolled
24 charts